MAFLD: an optimal framework for understanding liver cancer phenotypes DOI Creative Commons
Harry Crane, Cameron Gofton, Ankur Sharma

et al.

Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 58(10), P. 947 - 964

Published: July 20, 2023

Hepatocellular carcinoma has a substantial global mortality burden which is rising despite advancements in tackling the traditional viral risk factors. Metabolic (dysfunction) associated fatty liver disease (MAFLD) most prevalent disease, increasing parallel with epidemics of obesity, diabetes and systemic metabolic dysregulation. MAFLD major factor behind this sustained rise HCC incidence, both as single entity often via synergistic interactions other diseases. Mechanisms MAFLD-related are complex but crucially underpinned by dysregulation variable contributions from interacting modifiers related to environment, genetics, dysbiosis immune distinct clinical presentation, notably its common occurrence non-cirrhotic disease. This just one several challenges effective surveillance programmes. The response immune-checkpoint therapy currently controversial, further complicated high prevalence individuals aetiologies. In review, we highlight current data on epidemiology, characteristics, outcomes screening controversies. addition, concepts that have arisen because paradigm such MAFLD/NAFLD non-overlapping groups, dual aetiology tumours sub-phenotypes reviewed.

Language: Английский

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis DOI Creative Commons
Michael H. Le, David Le,

Thomas C. Baez

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: 30(2), P. 235 - 246

Published: Jan. 29, 2024

Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence NAFLD-related events.

Language: Английский

Citations

24
Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease DOI Creative Commons
Qingling Chen, Pingping Hu, Xiaoxue Hou

et al.

Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)

Published: July 4, 2024

Abstract Background The prognostic value of triglyceride-glucose (TyG) related indices in non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic (MASLD) is still unclear. This study aimed to determine the associations between TyG-related and long-term mortality this population. Methods data came from National Health Nutrition Examination Survey (NHANES III) Death Index (NDI). Baseline TyG, TyG combining with body mass index (TyG-BMI), waist circumference (TyG-WC) were calculated, status was determined through 31 December 2019. Multivariate Cox restricted cubic spline (RCS) regression models performed evaluate relationship among participants NAFLD/MASLD. In addition, we examined association all-cause within subgroups defined by age, sex, race/ethnicity, fibrosis-4 (FIB-4). Results There 10,390 completed ultrasonography laboratory included study. NAFLD diagnosed 3672/10,390 (35.3%) participants, while MASLD 3556/10,390 (34.2%) amongst overall multivariate analyses showed high levels indices, particularly TyG-BMI TyG-WC significantly associated mortality, cardiovascular diabetes either MASLD. RCS curves a nonlinear trend three Subgroup that more suitable for predicting patients without advanced fibrosis. Conclusion Our highlights clinical survival NAFLD/MASLD would be surrogate biomarkers follow-up population

Language: Английский

Citations

22
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study DOI
Eugene Han, Byung‐Wan Lee, Eun Seok Kang

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 152, P. 155789 - 155789

Published: Jan. 13, 2024

Language: Английский

Citations

18
MAFLD: Renovation of clinical practice and disease awareness of fatty liver DOI
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano

et al.

Hepatology Research, Journal Year: 2021, Volume and Issue: 52(5), P. 422 - 432

Published: Sept. 2, 2021

Recently, international expert panels have proposed a new definition of fatty liver: metabolic dysfunction-associated liver disease (MAFLD). MAFLD is not just simple renaming non-alcoholic (NAFLD). The unique feature the inclusion dysfunctions, which are high-risk factors for events. In addition, independent alcohol intake and co-existing causes disease. This concept may widespread impact on patients, medical doctors, staff, various stakeholders regarding liver. Thus, renovate clinical practice awareness this review, we introduce rationale MAFLD. We further describe representative cases showing how diagnostic processes differ between NAFLD. also summarize recent studies comparing with NAFLD discuss trials, Japanese populations, awareness.

Language: Английский

Citations

91
Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: Focusing on the non‐overlap groups DOI
Ibrahim Ayada, Laurens A. van Kleef,

Louise J. M. Alferink

et al.

Liver International, Journal Year: 2021, Volume and Issue: 42(2), P. 277 - 287

Published: Dec. 25, 2021

The applicability of the novel metabolic dysfunction associated fatty liver disease (MAFLD) definition has been studied in numerous cohorts and compared to non-alcoholic (NAFLD). No consensus reached on which is preferred. Therefore, this meta-analysis aims compare epidemiological clinical features NAFLD MAFLD general non-general population.We searched Medline, Embase Web Science for studies comparing NAFLD. Based status, following subgroups were investigated health: overlap (FLD), NAFLD-only MAFLD-only. Data pooled using random-effects models.We included 17 comprising 9 808 677 individuals. In population, was present 33.0% (95% CI 29.7%-36.5%) 29.1% 27.1%-31.1%). Among those with FLD, 4.0% 2.4%-6.4%) did not meet criteria but had (NAFLD-only) 15.1% 11.5%-19.5%) exclusively captured by (MAFLD-only). Notably, MAFLD-only group at significantly increased risk fibrosis (RR 4.2; 95% 1.3-12.9) higher alanine aminotransferase (mean difference: 8.0 U/L, 2.6-13.5) aspartate 6.4 3.0-9.7), NAFLD-only. Similar results obtained among population.Metabolic are highly prevalent considerable between them. However, NAFLD, more individuals additionally identified than missed. Importantly, criteria, damage identified. superior a population level.

Language: Английский

Citations

89
Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study DOI Open Access

Xiaomo Wang,

Shouling Wu, Xiaojie Yuan

et al.

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2021, Volume and Issue: 107(2), P. e745 - e755

Published: Sept. 1, 2021

Abstract Context Nonalcoholic fatty liver disease (NAFLD) was renamed metabolic dysfunction associated with (MAFLD) recently. Objective We aimed to explore the risk of all-cause deaths in MAFLD participants and compare it NAFLD Chinese adults. Methods enrolled 152 139 abdominal ultrasonography Kailuan Cohort from 2006 2012. categorized into non-MAFLD, non-NAFLD, 4 groups Neither FLD, only, MAFLD-NAFLD, respectively. used Cox regression models estimate hazard ratios (HRs) 95% CI death. Results The prevalence 31.5% 27.3%, After a median follow-up 12.7 years, both were increased mortality, especially men younger than 40 HR (95% CI) 1.51 (1.19-1.93) 1.37 (1.06-1.78), MAFLD-only group had higher mortality NAFLD-only males 60 years or older (adjusted = 1.43; CI, 1.00-2.03) lower aged 59 0.65; 0.48-0.90). overweight/obesity-only decreased, but those diabetes and/or dysregulation positive hepatitis B surface antigen excessive alcohol consumption further death, (HR 9.86; 2.44-39.98). Conclusion among population, which different according status overweight/obesity, diabetes, other indicators, second causes. patients should be managed by indicators causes fulfill precise treatment management.

Language: Английский

Citations

65
Metabolic dysfunction-associated fatty liver disease: a year in review DOI
Jawaher Alharthi, Amalia Gastaldelli,

Ian Homer

et al.

Current Opinion in Gastroenterology, Journal Year: 2022, Volume and Issue: 38(3), P. 251 - 260

Published: Feb. 9, 2022

Purpose of review In 2020, a novel comprehensive redefinition fatty liver disease was proposed by an international panel experts. This aims to explore current evidence regarding the impact this new definition on understanding epidemiology, pathogenesis, diagnosis, and clinical trials for disease. Recent findings The effectiveness metabolic dysfunction-associated (MAFLD) compared existing criteria nonalcoholic (NAFLD). data robustly suggest superior utility MAFLD in identifying patients at high risk dysfunction, hepatic extra-hepatic complications, as well those who would benefit from genetic testing, including with concomitant diseases. change name also appears have improved awareness among physicians. Summary transformation NAFLD represents important milestone, which indicates significant tangible progress towards more inclusive, equitable, patient-centred approach addressing profound challenges Growing has illustrated broader specific contexts that tremendous potential positively influencing diagnosis treatment. addition, momentum accompanying included widespread public attention unique burden previously underappreciated

Language: Английский

Citations

62
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name DOI Creative Commons
Cheng Han Ng, Daniel Q. Huang, Mindie H. Nguyen

et al.

Clinical and Molecular Hepatology, Journal Year: 2022, Volume and Issue: 28(4), P. 790 - 801

Published: May 11, 2022

Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world's adult population and is major public health concern. NAFLD defined by presence hepatic steatosis absence other causes disease. As closely associated with metabolic syndrome, several experts have called for change in nomenclature from to metabolic-associated (MAFLD) better reflect underlying pathophysiology as metabolically driven shift "positive" diagnostic criteria rather than one exclusion. Recent studies suggested that global prevalence MAFLD higher NAFLD, patients more comorbidities compared those NAFLD. Emerging data also suggest all-cause cardiovascular mortality may be In this synopsis, we discuss differences clinical features, outcomes between MAFLD. addition, highlight advantages disadvantages name perspective scientific community, care providers patients.

Language: Английский

Citations

56
MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups DOI
Hyoeun Kim, Chan Joo Lee, Sang Hoon Ahn

et al.

Digestive Diseases and Sciences, Journal Year: 2022, Volume and Issue: 67(10), P. 4919 - 4928

Published: May 17, 2022

Language: Английский

Citations

47
Metabolic dysfunction‐associated fatty liver disease and excessive alcohol consumption are both independent risk factors for mortality DOI Creative Commons
Laurens A. van Kleef, Robert J. de Knegt, Willem Pieter Brouwer

et al.

Hepatology, Journal Year: 2022, Volume and Issue: 77(3), P. 942 - 948

Published: July 1, 2022

MAFLD often cooccurs with excessive alcohol consumption, while its prognostic value in this group remains unclear. We aimed to study the mortality risk of relation consumption and potential interactions.We analyzed persons 25-74 years old enrolled National Health Nutrition Examination Survey III cohort available steatosis data. Participants viral hepatitis, body mass index < 18.5, missing data on age or follow-up were excluded, leaving 12,656 participants for analysis a median 22.9 [20.9-24.8] years. was defined as ultrasound presence metabolic dysfunction. Daily intake ≥10 g females ≥20 males considered consumption. quantified multivariate Cox regression Models adjusted age, squared, sex, race, marital status, education, smoking. present 31% 13% both independently simultaneously associated increased fully models (adjusted HR [aHR], 1.21; 95% CI, 1.13-1.30 aHR, 1.14; 1.04-1.26, respectively). Similarly, without (4.0%) expressed highest (aHR, 1.47; 1.28-1.71). Results consistent using initial 10 follow-up, stringent definition alcohol, propensity score weighting.MAFLD increases independent This underscores importance MAFLD, even patients

Language: Английский

Citations

46